Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis.
A 43-year-old patient developed factor V inhibitor 6 months after liver transplantation for primary biliary cirrhosis in association with Sjogren's syndrome/systemic lupus erythematosus. She suffered from ecchymoses in the lower extremities. The factor V inhibitor was eradicated after 10 weekly doses of 375-500 mg/m2 rituximab.
Lian
Eric Chun-Yet
EC
Department of Hematology/Oncology, University of Miami and Veterans Affairs Medical Center, Miami, Florida, USA. elian@med.miami.edu
Tzakis
Andreas G
AG
Andrews
David
D
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects* / Q000276:immunology; D005165:Factor V / Q000037:antagonists & inhibitors / Q000276:immunology*; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000097:blood / Q000150:complications / Q000276:immunology / Q000601:surgery; D016031:Liver Transplantation; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000150:complications / Q000276:immunology; D000069283:Rituximab; D012859:Sjogren's Syndrome / Q000097:blood / Q000150:complications / Q000276:immunology; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D000069283:Rituximab; D005165:Factor V